The Technical Analyst
Select Language :
Zealand Pharma A/S [ZEAL]

Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology

Zealand Pharma A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals

Zealand Pharma A/S is listed at the NASDAQ Exchange

0.00% $17.59

/ 29 sep 2022 @ 16:00


Zealand Pharma A/S: Main Fundamentals PE comparison

RATING 2022-11-02
B
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/201/212/213/213/211/22
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0 | sector: PE 0
PE RATIO: COMPANY / INDUSTRY
N/A
Company: PE 0 | industry: PE 0
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 16.50 - 18.68

( +/- 6.17%)
ATR Model: 14 days

Forecast: 01:40 - $19.14

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $17.59 (0.00% )
Volume 0.0022 mill
Avg. Vol. 0.0018 mill
% of Avg. Vol 122.64 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Zealand Pharma A/S

Last 12 Months

Last 12 months chart data with high, low, open and close for Zealand Pharma A/S

RSI

Intraday RSI14 chart for Zealand Pharma A/S

Last 10 Buy & Sell Signals For ZEAL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Zealand Pharma A/S

ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Last 10 Buy Signals

Date Signal @
RETH2USDMar 29 - 06:593 540.59
PUNDIXUSDMar 29 - 06:580.696
STRKUSDMar 29 - 06:58$14.20
ATMUSDMar 29 - 06:53$3.38
USDDUSDMar 29 - 06:480.997
ETHWUSDMar 29 - 06:484.35
GRTUSDMar 29 - 06:45$0.398
KCSUSDMar 29 - 06:44$11.84
GTUSDMar 29 - 06:43$9.65
WNXMUSDMar 29 - 06:3872.57

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.